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Abstract: The voltage-dependent L-type
Ca2+channel was identified as a macromo-
lecular target for (@)-englerin A. This
finding was reached by using an unprece-
dented ligand-based prediction platform
and the natural product piperlongumine as
a pharmacophore probe. (@)-Englerin A
features high substructure dissimilarity to
known ligands for voltage-dependent Ca2+
channels, selective binding affinity for the
dihydropyridine site, and potent modula-
tion of calcium signaling in muscle cells
and vascular tissue. The observed activity
was rationalized at the atomic level by
molecular dynamics simulations. Experi-
mental confirmation of this hitherto
unknown macromolecular target expands
the bioactivity space for this natural prod-
uct and corroborates the effectiveness of
chemocentric computational methods for
prioritizing target-based screens and iden-
tifying binding counterparts of complex
natural products.
Natural products have traditionally served as a privileged
source of chemical matter for interrogating biological systems
in chemical biology and drug-discovery programs.[1] Their
intricate architectures often allow the exploration of innova-
tive scaffolds in drug-relevant chemical space that is not
covered by synthetic small molecules.[2] However, factual
knowledge of macromolecular targets remains elusive for
most natural products, thus hindering the deployment of
rational approaches for lead and chemical-probe develop-
ment. Similarly, identification of off-targets for natural
products may decisively influence their validation as chemical
probes,[3] and improve the understanding of complex poly-
pharmacology networks in drug discovery.[4] Herein, we
disclose the voltage-dependent Ca2+ L-type (Cav1.2) channel
as a macromolecular target for the cancer-selective com-
pound (@)-englerin A [(@)-EA; Figure 1]. The (@)-EA/
Cav1.2 binding relationship was expeditiously recognized
from an unprecedented cross-natural-product target-infer-
ence approach, using a small molecule with similar pharma-
cophore features to (@)-EA as a tool compound, despite
substructural divergence. (@)-EA presents high affinity for
the dihydropyridine binding site in Cav1.2 channels, and
Figure 1. Computational target prediction to identify off-targets for (@)-EA. (@)-EA and its
volume are depicted in red and piperlongumine in green. A pharmacophore consensus
generated with Molecular Operating environment (MOE) is shown. Orange spheres:
aromatic/hydrophobic features, blue spheres: hydrogen-bond acceptor or its projected donor,
green sphere: hydrophobic feature. SPiDER performs ligand-based target prediction accord-
ing to topological descriptors. Images were generated with PyMOL (Schrçdinger LLC) or
MOE.
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potent calcium-modulating effects in muscle cell- and tissue-
based assays. Molecular dynamics (MD) simulations further
support the biology findings, and can be used to rationalize
key features of Cav1.2 recognition by (@)-EA.
To complement proteomic methods, chemical-structure-
driven algorithms may be swiftly deployed for steering
biology research efforts and target identification.[5] Specifi-
cally, the online SPiDER tool[6] employs topological pharma-
cophore[7] and physicochemical descriptors (Chemical Com-
puting Group, Montreal, Canada) to qualitatively infer
binding relationships between query ligands and macromo-
lecular targets. A statistical significance estimate (p value) is
derived for individual target predictions to support the
confidence of the prediction. Importantly, the “fuzziness” of
the employed descriptor renders this algorithm ideal to
predicting targets for natural products.[6b,c] Furthermore,
target inference from virtual natural product derived frag-
ments has been successfully achieved.[6b]
(@)-EA is a sesquiterpene extracted from Phyllanthus
engleri with selective and nanomolar-potent cytotoxicity
against renal cell carcinomas.[8] Its remarkable effects have
recently been ascribed to discriminating activation of the
transient receptor potential canonical 4/5 (TRPC4/5) chan-
nels, leading to intracellular Ca2+ overload and cell death.[9]
Considering the current high interest in (@)-EA as a chemical
probe/lead for anticancer drug discovery,[10] and taking into
account that drug-like molecules have been computationally
predicted to engage approximately 10 drug targets,[6a] we
initiated a pioneering program to rationally retrieve off-
targets and explore the underlying polypharmacological traits
of (@)-EA (Figure 1).
While the publicly available software tools SEA,[11]
SuperPred,[12] and PASS[13] did not afford confident target
predictions, the online SPiDER tool[6a] suggested only four
targets with confidence (Tables S2–4 in the Supporting
Information). Indeed, the result highlights unique structural
and pharmacophore features of (@)-EA, and supports its
documented renal cancer selective cytotoxicity.[11] The result
equally suggests that pharmacophore-based descriptors may
be better suited to predict targets for complex natural
products compared to substructure-based descriptors. Signifi-
cantly, SPiDER retrospectively predicted TRP channels with
confidence, thus corroborating the accuracy of the prediction
algorithm.
Building on these encouraging results and considering
that a limited array of macromolecular counterparts had been
confidently predicted for (@)-EA with state-of-the-art pre-
diction tools, we hypothesized that a fragment- and lead-like
natural product could serve as a pharmacophore surrogate to
yield target predictions easily transferrable to (@)-EA.
Simplification of parent natural product architectures has
previously been shown to afford synthetically tractable
entities with modest yet sustained bioactivity.[14] Hence, for
our chemical-genomics-inspired target-prediction program,
we identified the fragment-like anticancer agent piperlongu-
mine (PL, Figure 1) as a suitable chemical tool. Piperlongu-
mine is isolated from Piper longum and selectively kills cancer
cells by increasing the level of reactive oxygen species.[15]
Flexible ligand alignment between (@)-EA and PL (Figure 1)
corroborated the similar shapes and potentially shared
aromatic, hydrophobic, and hydrogen-bond-acceptor features
for molecular recognition, despite their profound substruc-
tural dissimilarity (Tanimoto index= 0.16, ECFP4 finger-
print). Target predictions for PL with SPiDER afforded 11
confidently predicted binding partners (Supporting Table S5),
which is in line with the previously reported average for small
molecules.[6a] The data fully support the rationale for our
approach, since both natural products are confidently pre-
dicted to bind to integrins and engage TRP channels. With
SPiDER target predictions in hand, we profiled both PL and
(@)-EA against the Cav1.2 channels. A radioligand displace-
ment assay revealed a modest affinity of PL for the
dihydropyridine binding pocket (19% binding inhibition at
50 mm). On the other hand, (@)-EA showed high affinity at
10 mm (72% radioligand displacement), while exhibiting
selectivity over the remaining binding sites (Figure 2a).
(@)-EA showed concentration-dependent radioligand dis-
placement and potent cooperative binding to the dihydropyr-
idine binding site (Hill slope> 2, Ki= 5.7: 0.4 mm, Figure 2b
and the Supporting Information).
From a pharmacophore perspective, the difference in
activity between PL and the complex (@)-EA can be
retrospectively explained on the basis of features unmet by
the fragment-like PL that may be critical for Cav1.2 binding,
for example, a H-bond donor (Figure 1). (@)-EA significantly
expands known Cav1.2 channel ligand space, since its nearest
neighbour in ChEMBL v20, CHEMBL201599, presents low
substructure similarity (Tanimoto index= 0.22, ECFP4 fin-
gerprint; Figure S3 in the Supporting Information).
The results highlight the accuracy of the prediction
algorithm and the cross-natural-product target-inference
strategy to identify unexpected ligand–target relationships
in the absence of substructural similarity to known target
modulators. The range of affinities of (@)-EA towards
different binding sites and the lack of detection of adducts
upon co-incubation with N- and C-protected cysteine suggest
specific non-covalent binding to Cav1.2 and an absence of
false-positive readouts. Dynamic light scattering experiments
at relevant concentrations support sample polydispersity with
an absence of artifactual binding (Figures S1, S2). (@)-EA
does not present measurable binding affinity towards the N-
type Ca2+ channel, nor does it engage two-pore calcium
channels 1/2 (TCP1/2), which demonstrates its selectivity
within a panel of selected voltage-gated Ca2+ channels
(Figure 2a, c and Figure S4).
To assess the biological relevance of the binding of
(@)-EA to Cav1.2, we performed calcium imaging using the
rat cardiomyocytic cell line H9C2. H9C2 cells lack expression
of the (@)-EA targets TRPC4/5, while expressing Cav1.2 upon
differentiation. Indeed, incubation with (@)-EA in concen-
trations as high as 10 mm did not induce any calcium influx in
undifferentiated H9C2 cells, thus suggesting that the cells are
devoid of TRPC4/5 expression (data not shown). We induced
H9C2 differentiation in low serum and 10 nm retionic acid as
previously described.[16] After five days of incubation, most
H9C2 cells appeared polynucleated and expressed Cav1.2, as
assessed by western blots probed with anti-Cav1.2 antibodies
(Figure S5). Polynucleated H9C2 cells showed a strong Ca2+
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influx when depolarized with 60 mm KCl, as measured by the
calcium-sensitive probe Fura-2 AM. A 45 min pre-treatment
with 6 mm (@)-EA or 10 mm nifedipine (control) significantly
reduced the KCl-induced Ca2+ influx (one-way ANOVA
amongst peak maxima for control [1%DMSO, (@)-EA (6 mm
in 1% DMSO), and nifedipine (10 mm in 1% DMSO), p<
0.0001; Figure 2d–f]. These observations are in line with the
hypothesis that (@)-EA blocks Cav1.2 channels. As an
orthogonal functional assay, we screened (@)-EA in endo-
thelium-denuded isolated rat thoracic aorta. To avoid con-
founding readouts, we blocked all G-protein-coupled recep-
tors that can interfere with Ca2+ signalling, that is, the a- and
b-adrenergic, histamine H1, muscarinic, and serotonin 5-HT2
receptors. As expected, KCl induced a concentration-depen-
dent tissue contraction, which was inhibited by nitrendipine.
Similarly, (@)-EA blocked the KCl-induced mechanical effect
in a concentration-dependent manner (EC50= 37: 1 mm ;
Figure 2g), thus corroborating the previously observed antag-
onism.
To provide a molecular rationale for this experimental
data, we performed MD simulations on the (@)-EA/Cav1.2
channel complex. Considering the fact that there are no
reported crystal structures for these channels, we used the
open-state Cav1.2 homology model reported by Zhorov
et al.[17] and performed molecular docking of (@)-EA into
the dihydropyridine binding site with AutoDock Vina.[18] The
binding pose with the best score was subjected to MD
simulations with AMBER12 in explicit water and Ca2+ ions
over 125 ns in a DOPC bilayer. The MD simulation trajectory
suggests that the ligand/Cav1.2 complex is stabilized by
hydrophobic interactions and a hydrogen bond. A CH@p
interaction is predicted between the phenyl ring in (@)-EA
and the methylene of the Phe202 side chain. Furthermore, the
hydroxy group of the ligand establishes a hydrogen bond,
populated approximately 92% of the total trajectory time,
with the backbone of Leu121 (Figure 3a). Interestingly, the
hydrogen bond is predicted to be transiently broken without
major shifts in the pose of (@)-EA, thus rationalizing the
importance of hydrophobic contacts for stabilization of the
ligand/receptor complex (Figure 3b). No significant interac-
tions with the binding pocket were observed in MD simu-
lations starting from diverse lower-scored (@)-EA poses or
for piperlongumine (Figure S6).
For ascertaining the importance of the predicted hydro-
gen bonding between (@)-EA and Leu121, we synthesized the
glycolic acid free analogue of (@)-EA, (@)-Englerin B
Figure 2. Engagement of Cav1.2 by (@)-Englerin A [(@)-EA]. a) Screening of (@)-EA and (@)-Englerin B [(@)-EB] in a radioligand displacement
assay against three different binding sites (verapamil, diltiazem, and dihydropyridine) of Cav1.2 and Cav2.2 at 10 mm. Error bars reflect the range
of two replicates. V=Verapamil; D=Diltiazem; DHP=Dihydropyridine. b) IC50 curve of (@)-EA against the dihydropyridine binding site
(Ki=5.7:0.4 mm ; Control: Nitrendipine, Ki=0.19 nm (nHill=2.1)). Error bars reflect the range of two replicates. c) Exemplary trace of the (@)-EA
screen against two-pore channels 1/2 (TPC1/2). Event 1 corresponds to the addition of either DMSO (0.1%) or (@)-EA (10 mm) and event 2
corresponds to addition of the Ca2+-releasing agent NAADP (100 nm). The data show no significant difference to the DMSO control. d) (@)-EA
and (@)-EB (6 mm) inhibit KCl-induced Ca2+ influx in rat cardiomyocytes. The normalized average of Fura-2 AM ratio of KCl-responding
polynucleated H9C2 cells was monitored for DMSO (n=61), (@)-EA (n=58), (@)-EB (n=66), and nifedipine (n=58). Non-responding cells
(<0.1 ratio increase) were not included in the analysis. e) A box plot of peak maxima after KCl stimulation of H9C2 cells (control: 1% DMSO;
(@)-EA, and (@)-EB: 6 mm in 1% DMSO; Nifedipine: 10 mm in 1% DMSO). One-way ANOVA amongst all response maxima after KCl stimulation:
**** p<0.0001. f) Live muscle cell calcium imaging. Exemplary images 5 s before KCl-induced [Ca2+]i maximum, at maximum and 5 s after KCl-
induced [Ca2+]i maximum (post-treatment). The Fura-2 AM ratio is color-coded as indicated (blue: low ratio, red: high ratio). g) Antagonism by
(@)-EA in endothelium-denuded isolated rat thoracic aorta (EC50=37:1 mm). Error bars reflect the range of two replicates.
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[(@)-EB], as previously described.[19] MD simulations with
the (@)-EB/Cav1.2 channel complex predicted no hydrogen
bonds over the total trajectory time. In fact, our data suggest
that a hydrogen bond with Leu121 might be important but not
the sole determinant for the affinity of (@)-EA, since its
analogue (@)-EB presents Ki> 10 mm against the dihydropyr-
idine binding site of Cav1.2, although with measurable
functional effects (Figures 2a,e). No appreciable affinity to
the verapamil and diltiazem binding sites in Cav1.2 and Cav2.2
was found for (@)-EB in radioligand displacement assays
(Figure 2a). Altogether, the in vitro data for both natural
products are commensurate with directed and specific target
interaction and corroborate the in silico rationale for molec-
ular recognition. Thus, selected structural features of (@)-EA
may be grafted onto small molecules in ligand-design
programmes.
Natural products remain an important source of chemical
matter in drug discovery. Nonetheless, their value as chemical
probes requires extensive validation and exploitation of on-/
off-target engagement effects and systems biology. (@)-EA
has recently attracted considerable attention in cancer
research. We experimentally confirmed the validity of our
pioneering target-prediction concept. We disclose functional
effects of (@)-EA on Ca2+ signalling pathways through Cav1.2
channel modulation, and identify the relevant molecular
recognition mechanisms. From a computational point of view,
the successful off-target identification can be ascribed to the
topological pharmacophore descriptors and consensus self-
organizing map method implemented in SPiDER, in contrast
to the substructure-based fingerprints implemented in other
tools. Whereas natural products display different architec-
tures compared to lead-like molecules, their potential phar-
macophore features are sufficiently similar to those of drug-
and lead-like molecules to allow confident target inferences.
It is noteworthy that false-positive predictions are still
expected with this or related platforms, and only previously
liganded macromolecules can be discovered as on- and off-
targets for the query natural products. That said, the results
suggest an expeditious chemogenomics-inspired platform to
rationally steer screening efforts and unveil hitherto unknown
pharmacology for complex chemotypes lying outside of drug-
like space and thus outside of the domain of applicability of
current state-of-the-art and publicly available target-predic-
tion tools.
Ultimately, we foresee a broad scope and prime utility of
related technologies to identify unexpected, although much
sought after, polypharmacology networks for intricate natural
products, and to leverage the design of natural product
inspired entities for chemical biology and molecular medi-
cine.
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